What Can ICER Learn from Big Tech Companies?

The Institute for Clinical and Economic Review’s (ICER) reputation has seen significant growth, but the author of a recent article posted on pharmaphorum says the nonprofit suffers from four key challenges.

Precision Health Economics & Outcomes Research’s Jason Shafrin says ICER’s lengthy report-based system fails to “account for the rapid flow of new information.”

“Making marginal changes to the model as new evidence arrives in real time is generally not possible,” Shafrin writes. “This approach is particularly problematic since evidence is often incomplete at drug launch.”

To read the full article, click here.